BioAtla, Inc.
BCAB
$0.83
$0.010.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 11.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 11.00M |
| Cost of Revenue | 9.54M | 567.00K | 12.36M | 11.65M | 16.40M |
| Gross Profit | -9.54M | -567.00K | -12.36M | -11.65M | -5.40M |
| SG&A Expenses | 4.25M | 4.96M | 5.26M | 4.59M | 5.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.79M | 18.65M | 17.61M | 16.24M | 22.27M |
| Operating Income | -13.79M | -18.65M | -17.61M | -16.24M | -11.27M |
| Income Before Tax | -15.78M | -18.71M | -15.33M | -14.88M | -10.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.78M | -18.71M | -15.33M | -14.88M | -10.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.78M | -18.71M | -15.33M | -14.88M | -10.59M |
| EBIT | -13.79M | -18.65M | -17.61M | -16.24M | -11.27M |
| EBITDA | -13.73M | -18.53M | -17.43M | -16.02M | -11.04M |
| EPS Basic | -0.27 | -0.32 | -0.26 | -0.30 | -0.22 |
| Normalized Basic EPS | -0.17 | -0.20 | -0.16 | -0.19 | -0.14 |
| EPS Diluted | -0.27 | -0.32 | -0.26 | -0.30 | -0.22 |
| Normalized Diluted EPS | -0.17 | -0.20 | -0.16 | -0.19 | -0.14 |
| Average Basic Shares Outstanding | 58.75M | 58.50M | 58.25M | 49.65M | 48.34M |
| Average Diluted Shares Outstanding | 58.75M | 58.50M | 58.25M | 49.65M | 48.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |